MICHAEL FARLEY: Open Payments
NPI 1548802416 · NAMPA, ID. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$946 in 40 payments from 10 companies in 2025. Trend: 2023 $834 · 2024 $453 · 2025 $946
Food & beverage: $946
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 15 | $342 |
| AstraZeneca Pharmaceuticals LP | 12 | $292 |
| ABBVIE INC. | 5 | $126 |
| Amgen Inc. | 2 | $44 |
| ABIOMED | 1 | $30 |
| ALK-Abello, Inc | 1 | $30 |
| PFIZER INC. | 1 | $27 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $21 |
| Lilly USA, LLC | 1 | $15 |
Products named: Rybelsus, AIRSUPRA, BREZTRI, Wegovy, QULIPTA, EVENITY, Ozempic, UBRELVY.
Industry payments across ID — which companies pay providers there.
